Xenetic Biosciences, Inc.

📍 Framingham, United States👥 8 employees💰 Last funded 2021
Biotechnology Research🌐 xeneticbio.com
Website LinkedIn
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Xenetic Biosciences, Inc.?
Xenetic Biosciences, Inc. has 2 investors on record on gritt.io.
When did Xenetic Biosciences, Inc. last raise funding?
The most recent investment in Xenetic Biosciences, Inc. recorded on gritt.io was in 2021.
What industry is Xenetic Biosciences, Inc. in?
Xenetic Biosciences, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Xenetic Biosciences, Inc. based?
Xenetic Biosciences, Inc. is headquartered in Framingham, United States.